Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the provided pages. The company plans to use approximately ₹200 crore available in its books (post buyback and dividend) for organic and inorganic growth opportunities. Investments are mainly focused on R&D and product development rather than raising external capital. The management emphasizes internal funding for growth, with ₹150 crore already invested in R&D over the last two years. No plans for external equity or debt fundraising were discussed during the Q&A or management commentary.

Any current/future capex/capital investment/strategic investment?

The company’s major investment focus is on R&D rather than traditional Capex, which is described as very limited or insignificant in the larger scheme of things. Recent R&D investments (close to ₹150 crores in last two years) target improving existing products and developing new ones, especially in zero trust, data privacy, endpoint security, and enterprise products. Strategic investment includes a sizable stake in an Israeli entity specializing in future technology (endpoint security), which is progressing well in product development. The company plans to use approximately ₹200 crore availabl

Future growth expectations in sales/revenue/volumes?

Enterprise business is growing rapidly (50% YoY growth in Q1 FY23) and currently forms about one-third of total revenue, with a target to reach a 50-50 mix with retail in the next two years. Retail (consumer) segment is relatively flat, with growth in India at about 1%, but the company maintains the highest market share (~30%). New products in Zero Trust, Data Privacy, EDR, and XDR are in beta/pilot stages; revenue from these is expected to start flowing from H1 FY24 onward. Future revenue growth will be driven by enterprise sales, with ongoing investment in R&D and marketing. Manageme

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims for a balanced revenue mix of 50-50 between retail and enterprise segments in the next two years, with enterprise expected to grow faster (around 11% globally). Current revenue growth is modest, with retail segment flat at about 1% growth in India, but enterprise business grew ~50% YoY in Q1 FY23. Significant investment in R&D (around ₹150 crore over two years) targets future products like Zero Trust and Data Privacy, expected to generate revenues starting H1 FY24. New product launches (e.g., Zero Trust User Access) have started onboarding customers, with revenue traction expe

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies Limited. Management emphasizes focus on product launches, particularly in enterprise security, with growing demand for new products like Zero Trust and Data Privacy solutions. They highlighted increasing traction and onboarding early customers for these new products, suggesting a growing pipeline. No specific quantitative details regarding order book size or pending orders were disclosed. Emphasis is on building product-market fit over 4 to 6 quarters, with revenues expec

Quick Heal Technologies LtdQ1 FY23IT - Software

Quick Heal Technologies Ltd Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹148Market Cap: ₹801 CrSector: IT - Software

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Enterprise business is growing rapidly (50% YoY growth in Q1 FY23) and currently forms about one-third of total revenue, with a target to reach a 50-50 mix with retail in the next two years.
Retail (consumer) segment is relatively flat, with growth in India at about 1%, but the company maintains the highest market share (~30%).
New products in Zero Trust, Data Privacy, EDR, and XDR are in beta/pilot stages; revenue from these is expected to start flowing from H1 FY24 onward.
Future revenue growth will be driven by enterprise sales, with ongoing investment in R&D and marketing.
Management’s vision targets reasonable revenue growth, focusing on building product-market fit for emerging technologies and expanding enterprise clientele, including larger organizations.
Awareness and demand generation, especially in enterprise, will influence future volume and sales growth.
Overall, expect modest retail growth, strong enterprise growth, and gradual revenue ramp-up from new cybersecurity products over the next 3-5 years.

Margin guidance

Category 3

The company aims for a balanced revenue mix of 50-50 between retail and enterprise segments in the next two years, with enterprise expected to grow faster (around 11% globally).
Current revenue growth is modest, with retail segment flat at about 1% growth in India, but enterprise business grew ~50% YoY in Q1 FY23.
Significant investment in R&D (around ₹150 crore over two years) targets future products like Zero Trust and Data Privacy, expected to generate revenues starting H1 FY24.
New product launches (e.g., Zero Trust User Access) have started onboarding customers, with revenue traction expected over 4-6 quarters.
Operating profits are impacted by increased R&D and sales & marketing expenses as part of growth investments.
The management expects reasonable revenue growth with continued cost optimization aiming for better profitability over the medium term.
EPS improvement has been supported by buybacks; organic growth in earnings is expected to pick up with new products gaining market acceptance.

See what Quick Heal Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising through debt or equity in the provided pages.
The company plans to use approximately ₹200 crore available in its books (post buyback and dividend) for organic and inorganic growth opportunities.
Investments are mainly focused on R&D and product development rather than raising external capital.
The management emphasizes internal funding for growth, with ₹150 crore already invested in R&D over the last two years.
No plans for external equity or debt fundraising were discussed during the Q&A or management commentary.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies Limited.
Management emphasizes focus on product launches, particularly in enterprise security, with growing demand for new products like Zero Trust and Data Privacy solutions.
They highlighted increasing traction and onboarding early customers for these new products, suggesting a growing pipeline.
No specific quantitative details regarding order book size or pending orders were disclosed.
Emphasis is on building product-market fit over 4 to 6 quarters, with revenues expected from H1 FY24.
Growth in enterprise segment revenue by around 50% YoY in Q1 FY23 indicates a robust order pipeline but no direct order book figures provided.
Overall, no concrete data on pending or confirmed orders is shared in the transcript.

See what Quick Heal Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

The company’s major investment focus is on R&D rather than traditional Capex, which is described as very limited or insignificant in the larger scheme of things.
Recent R&D investments (close to ₹150 crores in last two years) target improving existing products and developing new ones, especially in zero trust, data privacy, endpoint security, and enterprise products.
Strategic investment includes a sizable stake in an Israeli entity specializing in future technology (endpoint security), which is progressing well in product development.
The company plans to use approximately ₹200 crore available after buyback and dividend for organic and inorganic growth opportunities.
They have also onboarded a top global consultancy to help shape long-term strategic growth.
No major standalone Capex plans were mentioned, with emphasis placed on investment in product development and marketing to capture market growth.

Track Quick Heal Technologies Ltd — get its next earnings analysis in your feed

Margin guidance

Category 3

The company aims for a balanced revenue mix of 50-50 between retail and enterprise segments in the next two years, with enterprise expected to grow faster (around 11% globally).
Current revenue growth is modest, with retail segment flat at about 1% growth in India, but enterprise business grew ~50% YoY in Q1 FY23.
Significant investment in R&D (around ₹150 crore over two years) targets future products like Zero Trust and Data Privacy, expected to generate revenues starting H1 FY24.
New product launches (e.g., Zero Trust User Access) have started onboarding customers, with revenue traction expected over 4-6 quarters.
Operating profits are impacted by increased R&D and sales & marketing expenses as part of growth investments.
The management expects reasonable revenue growth with continued cost optimization aiming for better profitability over the medium term.
EPS improvement has been supported by buybacks; organic growth in earnings is expected to pick up with new products gaining market acceptance.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies Limited.
Management emphasizes focus on product launches, particularly in enterprise security, with growing demand for new products like Zero Trust and Data Privacy solutions.
They highlighted increasing traction and onboarding early customers for these new products, suggesting a growing pipeline.
No specific quantitative details regarding order book size or pending orders were disclosed.
Emphasis is on building product-market fit over 4 to 6 quarters, with revenues expected from H1 FY24.
Growth in enterprise segment revenue by around 50% YoY in Q1 FY23 indicates a robust order pipeline but no direct order book figures provided.
Overall, no concrete data on pending or confirmed orders is shared in the transcript.

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

ThisQuick Heal Technologies Ltd

Rev 3Mar 3

See where Quick Heal Technologies Ltd sits in IT - SoftwareSee which companies these are, and every other name in the sector.Open rankings

How does Quick Heal Technologies Ltd rank in IT - Software?

Compare Quick Heal Technologies Ltd against every IT - Software company (Q1 FY23) on revenue, margins and earnings-call signals.

View IT - Software leaderboard →

What Quick Heal Technologies Ltd's management said in earlier quarters

Others in IT - Software this season

Happiest Minds (Q1 FY27)
Geographic balance (38% Americas, 31% Europe, 31% rest of world) and sector diversification support stable growth (Page 11). Key concall takeaways from…
Sonata Software (Q1 FY27)
AI order book contributes 18.2% to the overall order book. Key concall takeaways from Sonata Software Ltd's Q1 FY27 earnings call — and how it ranks against…
XT Global Infotech Ltd (Q1 FY27)
Consolidated revenue grew modestly by 1.1% YoY; management indicates real growth driven by a shift from onsite to higher-margin offshore delivery. Key concall…
InfoBeans Technologies Ltd (Q1 FY27)
The company serves large enterprise clients with a high retention rate (94%), providing a stable revenue base and opportunity for expansion within existing…

Compare:vs TCS vs Infosys vs HCL Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Quick Heal Technologies Ltd Q1 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Quick Heal Technologies Ltd rank in IT - Software?

Continue your research

What Quick Heal Technologies Ltd's management said in earlier quarters

Others in IT - Software this season